A Multicenter, Single-Arm, Open-Label Treatment Use Protocol for Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Expanded access; Therapeutic Use
- Acronyms PEXIUS
- Sponsors Celgene Corporation
- 04 Jun 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
- 15 Feb 2013 New source identified and integrated (M.D. Anderson Cancer Center, 2012-0649).
- 15 Feb 2013 Planned number of patients 350 added as reported by M.D. Anderson Cancer Center record.